Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

125 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Protocol for a seamless phase 2A-phase 2B randomized double-blind placebo-controlled trial to evaluate the safety and efficacy of benfotiamine in patients with early Alzheimer's disease (BenfoTeam).
Feldman HH, Luchsinger JA, Léger GC, Taylor C, Jacobs DM, Salmon DP, Edland SD, Messer K, Revta C, Flowers SA, Jones KS, Koulman A, Yarasheski KE, Verghese PB, Venkatesh V, Zetterberg H, Durant J, Lupo JL, Gibson GE; ADCS BenfoTeam Study Group. Feldman HH, et al. PLoS One. 2024 May 29;19(5):e0302998. doi: 10.1371/journal.pone.0302998. eCollection 2024. PLoS One. 2024. PMID: 38809849 Free PMC article. Clinical Trial.
Clinical value of Alzheimer's disease biomarker testing.
Patel KJ, Yang D, Best JR, Chambers C, Lee PE, Henri-Bhargava A, Funnell CR, Foti DJ, Pettersen JA, Feldman HH, Nygaard HB, Hsiung GR, DeMarco ML. Patel KJ, et al. Among authors: feldman hh. Alzheimers Dement (N Y). 2024 Apr 8;10(2):e12464. doi: 10.1002/trc2.12464. eCollection 2024 Apr-Jun. Alzheimers Dement (N Y). 2024. PMID: 38596484 Free PMC article.
A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with Early Alzheimer's Disease.
Galasko D, Farlow MR, Lucey BP, Honig LS, Elbert D, Bateman R, Momper J, Thomas R, Rissman RA, Pa J, Aslanyan V, Balasubramanian A, West T, Maccecchini M, Feldman HH. Galasko D, et al. Among authors: feldman hh. medRxiv [Preprint]. 2024 Mar 22:2024.03.20.24304638. doi: 10.1101/2024.03.20.24304638. medRxiv. 2024. PMID: 38562783 Free PMC article. Preprint.
Asian Cohort for Alzheimer's Disease (ACAD) pilot study on genetic and non-genetic risk factors for Alzheimer's disease among Asian Americans and Canadians.
Ho PC, Yu WH, Tee BL, Lee WP, Li C, Gu Y, Yokoyama JS, Reyes-Dumeyer D, Choi YB, Yang HS, Vardarajan BN, Tzuang M, Lieu K, Lu A, Faber KM, Potter ZD, Revta C, Kirsch M, McCallum J, Mei D, Booth B, Cantwell LB, Chen F, Chou S, Clark D, Deng M, Hong TH, Hwang LJ, Jiang L, Joo Y, Kang Y, Kim ES, Kim H, Kim K, Kuzma AB, Lam E, Lanata SC, Lee K, Li D, Li M, Li X, Liu CL, Liu C, Liu L, Lupo JL, Nguyen K, Pfleuger SE, Qian J, Qian W, Ramirez V, Russ KA, Seo EH, Song YE, Tartaglia MC, Tian L, Torres M, Vo N, Wong EC, Xie Y, Yau EB, Yi I, Yu V, Zeng X, St George-Hyslop P, Au R, Schellenberg GD, Dage JL, Varma R, Hsiung GR, Rosen H, Henderson VW, Foroud T, Kukull WA, Peavy GM, Lee H, Feldman HH, Mayeux R, Chui H, Jun GR, Ta Park VM, Chow TW, Wang LS. Ho PC, et al. Among authors: feldman hh. Alzheimers Dement. 2024 Mar;20(3):2058-2071. doi: 10.1002/alz.13611. Epub 2024 Jan 12. Alzheimers Dement. 2024. PMID: 38215053 Free PMC article.
Efficacy assessment of an active tau immunotherapy in Alzheimer's disease patients with amyloid and tau pathology: a post hoc analysis of the "ADAMANT" randomised, placebo-controlled, double-blind, multi-centre, phase 2 clinical trial.
Cullen NC, Novak P, Tosun D, Kovacech B, Hanes J, Kontsekova E, Fresser M, Ropele S, Feldman HH, Schmidt R, Winblad B, Zilka N. Cullen NC, et al. Among authors: feldman hh. EBioMedicine. 2024 Jan;99:104923. doi: 10.1016/j.ebiom.2023.104923. Epub 2023 Dec 14. EBioMedicine. 2024. PMID: 38101301 Free PMC article. Clinical Trial.
Protocol for the Brain Health Support Program Study of the Canadian Therapeutic Platform Trial for Multidomain Interventions to Prevent Dementia (CAN-THUMBS UP): A Prospective 12-Month Intervention Study.
Feldman HH, Belleville S, Nygaard HB, Montero-Odasso M, Durant J, Lupo JL, Revta C, Chan S, Cuesta M, Slack PJ, Winer S, Brewster PWH, Hofer SM, Lim A, Centen A, Jacobs DM, Anderson ND, Walker JD, Speechley MR, Zou GY, Chertkow H. Feldman HH, et al. J Prev Alzheimers Dis. 2023;10(4):875-885. doi: 10.14283/jpad.2023.65. J Prev Alzheimers Dis. 2023. PMID: 37874110 Free PMC article.
Evaluation of bumetanide as a potential therapeutic agent for Alzheimer's disease.
Boyarko B, Podvin S, Greenberg B, Momper JD, Huang Y, Gerwick WH, Bang AG, Quinti L, Griciuc A, Kim DY, Tanzi RE, Feldman HH, Hook V. Boyarko B, et al. Among authors: feldman hh. Front Pharmacol. 2023 Aug 4;14:1190402. doi: 10.3389/fphar.2023.1190402. eCollection 2023. Front Pharmacol. 2023. PMID: 37601062 Free PMC article. Review.
125 results